Phase II trial of chemoradiotherapy (50.4Gy, modified 5-FU+CDDP) for clinical Stage II/III esophageal carcinoma

Phase II trial of chemoradiotherapy (50.4Gy, modified 5-FU+CDDP) for clinical Stage II/III esophageal carcinoma - Stage II/III esophageal carcinoma: CRT based on the RTOG regimen Phase II

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000856

Enrollment

Registered

2007-11-01

Start date

2006-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal cancer

Interventions

50.4Gy, modified 5-FU+CDDP chemoradiotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Thoracic esophageal cancer siagnosed as squamous cell carcinoma, adenocarcinoma or adenosquamous cell carcinoma. 2. Clinical UICC-stageII/III (non-T4) 3. No prior therpy for esophageal cancer and no chemotherapy for other disease 4. PS(ECOG): 0, 1 5. Not to select surgery 6. Written informed consent 7. Normal bone marrow, liver and renal function

Exclusion criteria

Exclusion criteria: 1. Fistula 2. Sever complications 3. Active infection 4. Past history of radiotherapy of chest 5. Intersitial pneumonia or fibrosis 6. Active double cancer 7. Pregnancy 8. Mental illness

Design outcomes

Primary

Measure	Time frame
1-year survival rate	—

Secondary

Measure	Time frame
3-year survival rate, progression free survival, CR rate, toxicity rate, late toxicity rate	—

Countries

Japan

Contacts

Public ContactTakako Eguchi Nakajima

National Cancer Center Hospital, Tokyo Outpatient Oncology

taeguchi@ncc.go.jp03-3542-2511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026